Sanofi (SAN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Sanofi (SAN)
Company Performance

Current Price

as of Oct 16, 2024

$109.25

P/E Ratio

29.77

Market Cap

$137.32B

Description

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Metrics

Overview

  • HQParis, IF
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerSAN
  • Price$109.254765-0.54%

Trading Information

  • Market Cap$137.32B
  • Float89.40%
  • Average Daily Volume (1m)1,550,062
  • Average Daily Volume (3m)1,454,517
  • EPS$4.31

Company

  • Revenue$43.07B
  • Rev Growth (1yr)0.17%
  • Net Income$5.40B
  • Gross Margin61.52%
  • EBITDA Margin30.09%
  • EBITDA$12.96B
  • EV$122.80B
  • EV/Revenue2.85
  • P/E29.77
  • P/S2.85
  • P/B1.73
Documents
Factset Street Account
StreetAccount Metrics Recap - Sanofi Q3 Earnings (€100.46, 0.00) (2023-10-27T05:52:03Z)
StreetAccount Consensus Metrics Preview - Sanofi Q3 Earnings (€100.62, -0.40) (2023-10-26T10:23:05Z)
Sanofi reports Q3 business EPS €2.55 vs consensus €2.61 (€100.46, 0.00) (2023-10-27T05:39:13Z)
Sanofi provided a comprehensive update regarding its Play to Win strategy (Pre EU Open) (€84.86, -15.60) (2023-10-27T08:57:21Z)
Sanofi preparing for spinoff of its consumer health division - Bloomberg ($45.32, -0.41) (2023-11-15T17:54:36Z)
Sanofi notes late-breaking amlitelimab Phase 2B data presented at EADV show potential best-in-class profile in atopic dermatitis (€104.14, +0.16) (2023-10-13T14:02:46Z)
Sanofi downgraded to hold from buy at Stifel (€81.44, 0.00) (2023-10-30T07:42:48Z)
Sanofi downgraded to hold from buy at Intron Health (€81.44, 0.00) (2023-10-30T07:30:19Z)
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli; Sanofi to pay $175M upfront to Janssen (€101.82, 0.00) (2023-10-03T06:37:17Z)
PNF investigation of Sanofi began in March - Bloomberg (€83.51, -1.43) (2023-11-07T10:31:57Z)
PNF investigating Sanofi for price fixing - La Lettre (pre-European open) (€84.27, -0.67) (2023-11-07T08:50:44Z)
Ligand acquires royalty on Sanofi's (SAN.FP) TZIELD for $20M ($52.29, 0.00) (2023-11-01T12:04:12Z)
EU's CHMP adopted a positive opinion recommending a change to the terms of the marketing authorisation for Sanofi Winthrop Industrie's Praluent (€103.94, -0.04) (2023-10-13T11:52:50Z)
EMA's PRAC says no conclusion yet on causal association between GLP-1 drugs and suicidal thoughts (2023-12-01T15:41:05Z)
EMA PRAC concludes no association between GLP-1 and thyroid cancer (earlier, 8ET) (2023-10-27T14:41:20Z)
Factset
Factset Business Description
Wikipedia
Sanofi